First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

Trial Details

NCT ID
NCT06644755
Phase
PHASE1
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • DS-2243a
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Leuven, Belgium|50.87959,4.70093
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • Sign and date the main ICF.
  • Adults ≥18 years at the time the biosample ICF or main ICF, whichever is signed first.
  • Follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old.
  • One of the following histologically or cytologically documented cancers:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →